Actualités Theratechnologies Inc - TH | Actions Toronto Stock Exchange

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Theratechnologies Reports on its Annual Meeting of Shareholders

MONTREAL, May 29, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV

VAMOS analysis highlights link between EVAF and reduced muscle quality Case series reports success with...

Theratechnologies Provides Update on Sale Process

MONTREAL, April 15, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company

MONTREAL, April 11, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

FDA Approves EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and...

Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA

FDA action allows for unrestricted distribution of EGRIFTA SV®, removing uncertainty with respect to all...

Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update

MONTREAL, April 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy

New, improved formulation set to replace EGRIFTA SV® MONTREAL, March 25, 2025 (GLOBE NEWSWIRE...

Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV

MONTREAL, March 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Theratechnologies Inc (TH)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

TH Actualités

Theratechnologies Reports on its Annual Meeting of Shareholders

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV

Theratechnologies Provides Update on Sale Process

Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA

Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update

Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy

Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024

Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Theratechnologies Resumes Distribution of EGRIFTA SV®

Theratechnologies Provides Update on EGRIFTA SV® Supply

Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Theratechnologies Inc (TH) Actualités

Theratechnologies Inc (TH)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

TH Actualités

Theratechnologies Reports on its Annual Meeting of Shareholders

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV

Theratechnologies Provides Update on Sale Process

Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA

Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update

Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy

Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024

Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Theratechnologies Resumes Distribution of EGRIFTA SV®

Theratechnologies Provides Update on EGRIFTA SV® Supply

Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Connectez-vous

Supprimer les publicités